Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.70 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255586 | 0.94 | EGFR (0.74) | EGFRERBB2ERBB4AURKBHDAC3 | |
| SCHEMBL27819297 | 0.92 | EGFR (0.74) | EGFRERBB2ERBB4AURKBHDAC3 | |
| SCHEMBL5497185 | 0.88 | EGFR (0.72) | EGFRERBB2ERBB4AURKBHDAC3 | |
| SCHEMBL2250814 | 0.88 | EGFR (0.68) | EGFRERBB2ERBB4AURKBHDAC3 | |
| SCHEMBL2245963 | 0.86 | EGFR (0.66) | EGFRERBB2ERBB4AURKBHDAC3 | |
| SCHEMBL2251187 | 0.85 | EGFR (0.78) | EGFRERBB2ERBB4AURKB | |
| SCHEMBL27923377 | 0.84 | EGFR (0.75) | EGFRERBB2ERBB4AURKB | |
| SCHEMBL2249790 | 0.84 | EGFR (0.83) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL2251606 | 0.83 | EGFR (0.75) | EGFRERBB2ERBB4AURKBHDAC3 | |
| SCHEMBL2248288 | 0.83 | EGFR (0.65) | EGFRERBB2ERBB4AURKBHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| CN-101094840-B | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD | 2012-10-31 | — | — | CN | disclosed |
| US-8003658-B2 | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-23 | — | — | US | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
| CN-101094840-A | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD (KR) | 2007-12-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 1400/4885ERBB2 1693/4885ERBB4 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.